ARTV on Nasdaq
Artiva Biotherapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with CytRx, PALISADE BIO, INC. or Inhibikase Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| License and development support revenue (including related party amounts of $0 and $251, respectively) | $0 | $251.0K |
| Research and development (including related party amounts of $76 and $3,168, respectively) | $69.5M | $50.3M |
| General and administrative | $20.3M | $17.2M |
| Total operating expenses | $89.8M | $67.5M |
| Loss from operations | -$89.8M | -$67.3M |
| Interest income | $6.0M | $5.3M |
| Change in fair value of SAFEs (including related party amounts of $0 and $2,911, respectively) | $0 | -$3.6M |
| Other (expense) income, net | -$14.0K | $157.0K |
| Total other income, net | $5.9M | $1.9M |
| Net loss per share - basic | -$3.43 | -$5.81 |
| Net loss per share - diluted | -$3.43 | -$5.81 |
| Weighted average common shares outstanding - basic | 24.4M shares | 11.3M shares |
| Weighted average common shares outstanding - diluted | 24.4M shares | 11.3M shares |
| Net Income (Loss) | -$83.9M | -$65.4M |
| Unrealized gain (loss) on investments, net | $232.0K | -$437.0K |
| Comprehensive loss | -$83.6M | -$65.8M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-07-31 |
|---|---|---|---|
| Cash and cash equivalents | $26.7M | $40.2M | |
| Short-term investments | $81.3M | $145.2M | |
| Other receivables (including related party amounts of $61 and $0, respectively) | $67.0K | $146.0K | |
| Prepaid expenses and other current assets | $4.6M | $3.1M | |
| Total current assets | $112.7M | $188.6M | |
| Restricted cash | $461.0K | $258.0K | |
| Property and equipment, net | $6.6M | $6.4M | |
| Operating lease right-of-use assets | $10.5M | $13.8M | |
| Financing lease right-of-use asset | $212.0K | $261.0K | |
| Other long-term assets | $458.0K | $267.0K | |
| Total assets | $130.9M | $209.6M | |
| Accounts payable (including related party amounts of $0 and $276, respectively) | $355.0K | $1.1M | |
| Current portion of operating lease liabilities | $3.0M | $3.6M | |
| Current portion of financing lease liability | $44.0K | $122.0K | |
| Other current liabilities | $73.0K | ||
| Total current liabilities | $13.1M | $12.3M | |
| Operating lease liabilities, net of current portion | $7.9M | $10.6M | |
| Financing lease liability, net of current portion | $44.0K | ||
| Other non-current liabilities | $73.0K | ||
| Total liabilities | $21.0M | $22.9M | |
| Common stock, $0.0001 par value; 700,000,000 shares authorized at December 31, 2025 and December 31, 2024; 24,595,550 and 24,291,607 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $3.0K | $3.0K | |
| Additional paid-in capital | $440.4M | $433.5M | |
| Accumulated other comprehensive income (loss) | $103.0K | -$129.0K | |
| Accumulated deficit | -$330.5M | -$246.7M | |
| Total stockholders' equity | $110.0M | $186.6M | |
| Total liabilities and stockholders' equity | $130.9M | $209.6M | |
| Accrued expenses | $9.6M | $7.4M | |
| Preferred stock shares authorized | 10.0M shares | ||
| Common stock par or stated value per share | $0.00 | ||
| Common stock shares authorized | 700.0M shares | ||
| Common stock shares issued | 424.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | -$83.9M | -$65.4M |
| Depreciation and amortization | $2.6M | $2.4M |
| Stock-based compensation | $6.8M | $7.0M |
| Change in fair value of SAFEs (including related party amounts of $0 and $2,911, respectively) | $0 | $3.6M |
| Accretion of discounts and amortization of premiums on investments, net | -$1.9M | -$2.3M |
| Accounts receivable (including related party amounts of $0 and $569, respectively) | $0 | $1.0M |
| Other receivables (including related party amounts of $(61) and $607, respectively) | $79.0K | $578.0K |
| Prepaid expenses and other current assets | -$1.5M | -$2.0M |
| Other long-term assets | -$191.0K | $125.0K |
| Accrued expenses (including related party amounts of $(735) and $(1,447), respectively) | $2.0M | -$659.0K |
| Operating lease right-of-use asset and lease liabilities, net | -$21.0K | $43.0K |
| Net cash used in operating activities | -$76.8M | -$55.0M |
| Purchases of property and equipment | -$2.6M | -$642.0K |
| Purchases of investments | -$44.9M | -$176.2M |
| Maturities of investments | $110.9M | $56.4M |
| Net cash provided by (used in) investing activities | $63.4M | -$120.5M |
| Proceeds from issuance of common stock, net of commissions | $0 | $166.5M |
| Proceeds from exercise of stock options | $138.0K | $51.0K |
| Proceeds from purchase of ESPP shares | $233.0K | $0 |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | -$230.0K | $0 |
| Payments on finance leases | -$132.0K | -$149.0K |
| Cash paid in connection with IPO offering costs | $0 | -$4.2M |
| Net cash provided by financing activities | $9.0K | $162.2M |
| Net decrease in cash, cash equivalents and restricted cash | -$13.3M | -$13.3M |
| Right-of-use asset obtained in exchange for new operating lease liability | $442.0K | $0 |
| Reduction in operating lease liabilities and right-of-use-assets from remeasurement | $546.0K | $0 |
| Property and equipment purchases in accounts payable and accrued liabilities | $292.0K | $57.0K |
| Conversion of SAFE notes to common stock | $0 | $28.7M |
| Conversion of preferred stock to common stock | $0 | $216.4M |
| Non-cash additions to financing leases | $0 | $241.0K |
| Accounts payable including related party | -$760.0K | $519.0K |
Recent filings
- Oct 7, 20264
- Oct 6, 20264
- Oct 6, 20264
- Oct 6, 20264
- Oct 6, 20264
- Oct 6, 2026144
- Sep 15, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 14, 20264
- Sep 14, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6